Current challenges in HER2-positive breast cancer

详细信息    查看全文

• 作者：Fabio Puglisi^a ; ^b ; ^{fabio.puglisi@uniud.it" class="auth_mail" title="E-mail the corresponding author}Author Vitae ; Caterina Fontanella^a ; ^b ; Vito Amoroso^c ; Giulia Valeria Bianchi^d ; Giancarlo Bisagni^e ; Cristina Falci^f ; Andrea Fontana^g ; Daniele Generali^h ; Lorenzo Gianniⁱ ; Antonio Grassadonia^j ; Luca Moscetti^k ; Ilaria Portarena^l ; Emanuela Rossi^m ; Paolo Marchettiⁿ
• 关键词：Breast cancer ; Dual targeting ; HER2 ; Lapatinib ; Neoadjuvant ; Pertuzumab ; Trastuzumab ; Trastuzumab-emtansine
• 刊名：Critical Reviews in Oncology and Hematology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：98
• 期：Complete
• 页码：211-221
• 全文大小：1264 K

文摘

The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.

This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.